agilon health, inc. Board Changes and Officer Compensation
Ticker: AGL · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1831097
| Field | Detail |
|---|---|
| Company | Agilon Health, Inc. (AGL) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $625,000, $2,500,000, $1,000,000, $3,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: AGIL
TL;DR
agilon health board shakeup: 2 out, 2 in. New exec comp details out.
AI Summary
On June 4, 2024, agilon health, inc. announced a change in its board of directors, with Dr. Paul M. R. Thomas and Ms. Sarah M. Davis resigning. Concurrently, Mr. David L. Snow and Ms. Jennifer L. Wagner were appointed as new directors. The company also disclosed compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are important for understanding executive incentives and potential dilution.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can impact investor confidence and signal potential strategic shifts or financial implications.
Key Players & Entities
- agilon health, inc. (company) — Registrant
- Dr. Paul M. R. Thomas (person) — Resigning Director
- Ms. Sarah M. Davis (person) — Resigning Director
- Mr. David L. Snow (person) — Appointed Director
- Ms. Jennifer L. Wagner (person) — Appointed Director
FAQ
Who resigned from agilon health's board of directors?
Dr. Paul M. R. Thomas and Ms. Sarah M. Davis resigned from the board of directors.
Who was appointed to agilon health's board of directors?
Mr. David L. Snow and Ms. Jennifer L. Wagner were appointed as new directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 4, 2024.
What are the primary items disclosed in this 8-K filing?
The filing discloses the departure of directors, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, along with Regulation FD disclosures and financial statements/exhibits.
What is agilon health, inc.'s state of incorporation and IRS number?
agilon health, inc. is incorporated in Delaware and its IRS Employer Identification Number is 37-1915147.
Filing Stats: 1,151 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2024-06-05 08:05:47
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share AGL The New York Stock Exchan
- $625,000 — e will receive an annual base salary of $625,000 and an annual target bonus of 75% of hi
- $2,500,000 — ("RSUs")with a grant-date fair value of $2,500,000 vesting on a three-year pro rata basis,
- $1,000,000 — "PSUs") with a grant-date fair value of $1,000,000 with a +100% share price appreciation h
- $3,500,000 — wards having a grant-date fair value of $3,500,000 in the aggregate, with an equity award
- $300,000 — ke will also receive a sign on bonus of $300,000 in a single lump sum between 30 and 45
Filing Documents
- agl-20240604.htm (8-K) — 34KB
- agl-8kx06042024xex991.htm (EX-99.1) — 15KB
- image_0a.jpg (GRAPHIC) — 12KB
- 0001628280-24-026758.txt ( ) — 246KB
- agl-20240604.xsd (EX-101.SCH) — 2KB
- agl-20240604_lab.xml (EX-101.LAB) — 22KB
- agl-20240604_pre.xml (EX-101.PRE) — 24KB
- agl-20240604_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 5, 2024, the Company issued a press release announcing the appointment of Mr. Schwaneke as Chief Financial Officer and Executive Vice President. A copy of the press release is attached hereto as Exhibit 99.1 to this report and is incorporated in this Item 7.01 by reference . The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under theSecurities Act of 1933, as amended, or theExchange Act, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated June 5, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. agilon health, inc. Date: June 5, 2024 By: /s/ DENISE V. ZAMORE Denise V. Zamore Executive Vice President, Chief Legal Officer & Corporate Secretary